173 related articles for article (PubMed ID: 31945621)
1. Clinicopathologic determinants of pathologic treatment response in neoadjuvant treated rectal adenocarcinoma.
González I; Bauer PS; Chapman WC; Alipour Z; Rais R; Liu J; Chatterjee D
Ann Diagn Pathol; 2020 Apr; 45():151452. PubMed ID: 31945621
[TBL] [Abstract][Full Text] [Related]
2. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.
Agarwal A; Chang GJ; Hu CY; Taggart M; Rashid A; Park IJ; You YN; Das P; Krishnan S; Crane CH; Rodriguez-Bigas M; Skibber J; Ellis L; Eng C; Kopetz S; Maru DM
Cancer; 2013 Dec; 119(24):4231-41. PubMed ID: 24089344
[TBL] [Abstract][Full Text] [Related]
3. Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.
Zhang Q; Liang J; Chen J; Mei S; Wang Z
Asian Pac J Cancer Prev; 2021 May; 22(5):1607-1611. PubMed ID: 34048192
[TBL] [Abstract][Full Text] [Related]
4. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
[TBL] [Abstract][Full Text] [Related]
5. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].
Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I
Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600
[TBL] [Abstract][Full Text] [Related]
6. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
7. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
8. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
[TBL] [Abstract][Full Text] [Related]
9. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy.
Shia J; McManus M; Guillem JG; Leibold T; Zhou Q; Tang LH; Riedel ER; Weiser MR; Paty PB; Temple LK; Nash G; Kolosov K; Minsky BD; Wong WD; Klimstra DS
Am J Surg Pathol; 2011 Jan; 35(1):127-34. PubMed ID: 21164296
[TBL] [Abstract][Full Text] [Related]
10. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
11. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
12. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.
Nguyen P; Wuthrick E; Chablani P; Robinson A; Simmons L; Wu C; Arnold M; Harzman AE; Husain S; Schmidt C; Abdel-Misih S; Bekaii-Saab T; Chakravarti A; Williams TM
Am J Clin Oncol; 2018 Feb; 41(2):140-146. PubMed ID: 26535992
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response implies a fewer number of lymph nodes in specimen of rectal cancer patients treated by neoadjuvant therapy and total mesorectal excision.
Bustamante-Lopez LA; Nahas CSR; Nahas SC; Marques CFS; Pinto RA; Cotti GC; Imperiale AR; de Mello ES; Ribeiro U; Cecconello I
Int J Surg; 2018 Aug; 56():283-287. PubMed ID: 29981939
[TBL] [Abstract][Full Text] [Related]
14. Impact of residual nodal involvement after complete tumor response in patients undergoing neoadjuvant (chemo)radiotherapy for rectal cancer.
Erkan A; Mendez A; Trepanier M; Kelly J; Nassif G; Albert MR; Lee L; Monson JRT
Surgery; 2019 Oct; 166(4):648-654. PubMed ID: 31378480
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
16. [Predictive factors associated with pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
Sun Y; Chi P; Xu B; Lin H; Lu X; Huang Y; Xu Z; Huang S; Jiang C
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Jun; 17(6):556-60. PubMed ID: 24953361
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer.
Sada YH; Tran Cao HS; Chang GJ; Artinyan A; Musher BL; Smaglo BG; Massarweh NN
J Surg Res; 2018 Jun; 226():15-23. PubMed ID: 29661280
[TBL] [Abstract][Full Text] [Related]
19. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
20. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
